I was recently invited to perform a resection of a tumor in the tail of the pancreatic body. Before going on stage, the surgery had already been performed with open abdomen and abdominal exploration. The physician on stage reported that the patient had extensive metastases and had no chance of surgical resection. This patient had no signs of distant metastasis on preoperative imaging and physical examination, and the main difficulty with the tumor was its proximity to the root of the splenic artery with no other significant vascular invasion. I came on stage and explored the pelvis, abdominal wall, and kidneys without tumor dissemination. The pancreas broke through the peritoneum and there were more scattered foci of dissemination in the lesser omentum, the gastric wall, and the caudate lobe of the liver, as large as a soybean and as small as the size of a grain of rice. This situation gives the impression of an advanced abdominal dissemination, which seems to be unresectable. But whether it can be resected or not cannot be guided by feeling alone during operation. Pancreatic cancer staging should be used as a criterion to determine whether the cancer in the tail of the pancreatic body can be resected or not. According to the Japanese JPS staging and UICC/AJCC staging, this case was staged T3N1M0, stage IIB, with indication for surgical resection. We resected the pancreatic tumor about 1 cm to the right of the superior mesenteric artery, removed the spleen, 2/3/4/5/6/7/8/9/10/11/12, and group lymph nodes together, and the gastric wall implant foci were located in the plasma membrane, and the plasma membrane tissue was removed from the implant site. The hepatic caudate lobe implant foci were resected together. UICC has guiding opinions on whether pancreatic cancer can be resected or not before surgery. In our work, some patients who seem to be unresectable or have poor prognosis after resection have long-term survival after surgical resection. Example 1 Pancreatic body tail cancer adjacent to superior mesenteric artery, tumor-free survival for 1 year since surgery. Case 2: Pancreatic body tail cancer with thrombosis of splenic vein and inferior mesenteric vein, tumor-free survival for 9 months since surgery. In conclusion, as long as there is no obvious invasion of abdominal artery and superior mesenteric artery and no distant metastasis, the tumor in the tail of pancreatic body should be actively treated to see if it can be surgically resected. Together with postoperative comprehensive treatment, all of them can achieve better results.